Alkermes plc DEFA14A, filed Jun 6, 2023

Alkermes plc. (ALKS)

DEFA14A 2023-06-06

Added on October 15, 2026



Filed by the Registrant x

Filed by a Party other than the Registrant o

Check the appropriate box:
o	Preliminary Proxy Statement
o	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o	Definitive Proxy Statement
x	Definitive Additional Materials
o	Soliciting Material under §240.14a-12

ALKERMES PLC
(Name of Registrant as Specified In Its Charter)


(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):
x	No fee required.
o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)		Title of each class of securities to which transaction applies:

	(2)		Aggregate number of securities to which transaction applies:

	(3)		Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	(4)		Proposed maximum aggregate value of transaction:

	(5)		Total fee paid:

o	Fee paid previously with preliminary materials.
o	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:


In millions (except per share amounts)	Updated 2023 Expectations (Provided June 6, 2023)	Prior 2023 Expectations (Provided April 26, 2023)

Total Revenue	$1,550 – $1,680	$1,130 – $1,250
VIVITROL®Net Sales	$380 – $410	$380 – $410
ARISTADA®Net Sales	$315 – $345	$315 – $345
LYBALVI®Net Sales	$180 – $205	$180 – $205
INVEGA Franchise Royalties related to 2023	$265 – $280	$40 – $45*
Royalties and interest related to 2022	~$195	-
Other Revenues	$215 – $245	$215 – $245
Cost of Goods Sold	$230 – $250	$230 – $250
R&D Expenses	$370 – $400	$370 – $400
SG&A Expenses	$695 – $725	$695 – $725
Amortization of Intangible Assets	~$35	~$35


Interest Expense, Net	$5 – $10	$5 – $10
Income Tax Benefit	$5 – $10	$5 – $10
GAAP Net Income (Loss)	$225 – $265	($160) – ($200)
GAAP Earnings (Loss) per Share (Diluted)+	$1.31 – $1.54	($0.96) – ($1.20)
Non-GAAP Net Income†	$230 – $270	$0 – $40
Non-GAAP Earnings Per Share (Diluted)+	$1.34 – $1.57	$0.00 – $0.23
Capital Expenditures	$35 – $40	$35 – $40


Alkermes plc and Subsidiaries
2023 Guidance — GAAP to Non-GAAP Adjustments

An itemized reconciliation between projected diluted earnings per share on a GAAP basis and projected diluted earnings per share on a non-GAAP basis is as follows:

(In millions, except per share data)	Amount			Shares		Earnings Per Share
Projected Net Income — GAAP	$	245.0			171.5	$	1.43
Adjustments:
Share-based compensation expense		97.5
Depreciation expense		42.5
Amortization expense		35.0
Separation expense		21.0
Income tax effect related to reconciling items		3.5
Non-cash net interest expense		0.5
Royalties and interest related to 2022*		(195.0	)
Projected Net Income — Non-GAAP	$	250.0			171.5	$	1.46

Projected GAAP and non-GAAP measures reflect mid-points within ranges of estimated guidance.
* Pursuant to final award related to arbitration proceedings with Janssen Pharmaceutica N.V.